New Delhi: Germany’s BioNTech SE mentioned on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialize its cancer antibody drug candidate.
OncoC4 will get a $200 million upfront cost and is eligible to obtain growth, regulatory, and business milestone funds in addition to double-digit tiered royalties.
The firms mentioned they are going to co-develop the candidate, ONC-392, as a monotherapy or as a mixture remedy in varied cancer indications.
A late-stage trial for the drug has been deliberate for this yr, the businesses mentioned.
Follow and join with us on Twitter, Facebook, Linkedin, Youtube
